Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,067 recruiting studies in this area right now.
By phase
- Not applicable3,005
- Phase 21,060
- Phase 1794
- Phase 1/Phase 2441
- Phase 3435
- Phase 4233
- Phase 2/Phase 399
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma328
- Asthma194
- Lymphoma179
- Type 1 Diabetes132
- Rheumatoid Arthritis131
- Atopic Dermatitis122
- Systemic Lupus Erythematosus121
- Acute Lymphoblastic Leukemia118
- HIV Infections105
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases79
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca64
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center49
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California498
- Maryland198
- Alabama178
- Florida151
- Arizona150
- Massachusetts118
- New York114
- Texas112
- Illinois84
- Colorado81
Recruiting studies6,067 total
- NCT05795140RecruitingPhase 3
Long-term safety study of iptacopan for aHUS
This study follows people with aHUS who are already taking iptacopan to check how well it continues to work and how safe it is over the long term. You may be asked to keep taking the study medicine and follow extra safety rules, including infection and pregnancy precautions.
São Paulo, São PauloAges 18–100 - NCT05751798RecruitingPhase 1/Phase 2
Test drug OSE-279 for advanced lung cancer that has no key mutations
This Phase 1/2 study tests how well and how safely OSE-279 works in people with advanced non-small cell lung cancer (NSCLC) who cannot be cured with surgery or radiation. It also looks at the right dose and how it may help, especially if the tumor has high PD-L1.
AnderlechtAges 18 years+ - NCT05768529RecruitingPhase 1/Phase 2
U16 cell therapy for relapsed or refractory B-cell lymphoma
This trial tests a new cell therapy called U16 for people with certain types of B-cell lymphoma that have come back or not responded to previous treatments. The therapy uses your own immune cells to target and attack the cancer cells.
Changsha, HunanAges 18–70 - NCT05748171RecruitingPhase 2
Testing inotuzumab for children with early ALL relapse
This Phase 2 study tests inotuzumab ozogamicin (InO), a cancer medicine, in children aged 1 to under 18 with a first relapse of ALL. It aims to find out how well and safely the medicine works when the leukemia comes back early.
ViennaAges 1–17 - NCT05765812RecruitingPhase 1/Phase 2
Debio 0123 with temozolomide for recurrent or new glioblastoma
This early-phase study tests Debio 0123 (an anticancer medicine) combined with temozolomide, and for newly diagnosed patients also with radiation. It aims to see whether this treatment combination can slow or control glioblastoma in adults.
Chicago, IllinoisAges 18 years+ - NCT05754710Recruiting
Kids taking Xeljanz for juvenile arthritis study
This study is collecting real-world information about how Xeljanz (tofacitinib) is used and how well it works in children with juvenile idiopathic arthritis. It may help improve how the medicine is used safely in everyday care.
SeoulAges 2–17 - NCT05754450RecruitingPhase 3
Extension study for AVTX-803 in LAD type II
This trial is a follow-up study testing whether AVTX-803 continues to be safe and effective for people with Leukocyte Adhesion Deficiency type II (LAD II). If you already took part in an earlier AVTX-803 LAD II study, this may be the next step while researchers monitor benefits and side effects.
Rochester, MinnesotaAges 6 months–75 years - NCT05757102RecruitingPhase 3
Test new inhaler combo versus standard inhaler in teens
This Phase 3 trial compares a triple inhaler (FF/UMEC/VI) against the usual double inhaler (FF/VI) to help control asthma symptoms and breathing tests in teens ages 12–17. It also checks how safe and tolerable the treatments are over the study period.
Birmingham, AlabamaAges 12–17 - NCT05757219RecruitingPhase 2
Itacitinib before CAR T for aggressive B-cell lymphoma
This trial tests itacitinib given before CAR T cell therapy to see if it can improve outcomes for people with diffuse large B-cell lymphoma (DLBCL). It may help by calming certain immune signals before CAR T is started.
Tampa, FloridaAges 18 years+ - NCT05776511Recruiting
Eye Movement Test for White Matter Brain Changes
This study tests whether a special eye-tracking camera can help diagnose the cause of white matter hypersignals—unusual bright spots seen on brain MRI. Researchers want to see if eye movements can reveal clues about what's causing these brain changes.
NiceAges 18 years+ - NCT05773040RecruitingPhase 1
CAR T-cell therapy made from your own immune cells
This Phase 1 trial tests an “autologous” CAR T-cell treatment (made from your own T cells) that targets a cancer marker called CD79b in certain relapsed or hard-to-treat B-cell lymphomas. It’s designed to find a safe dose and see whether the treatment can shrink tumors and help control the lymphoma after prior therapies.
Houston, TexasAges 18 years+ - NCT05775718RecruitingPhase 2
Shingrix shot after bone marrow transplant to prevent shingles
This Phase 2 study tests whether an additional Shingrix (RZV) vaccine dose helps prevent shingles in people who previously had an allogeneic bone marrow or stem cell transplant. It focuses on people who are at least a year out from their first two Shingrix doses.
Aurora, ColoradoAges 18–79 - NCT05776979RecruitingPhase 2
Isatuximab plus lenalidomide after transplant for high-risk myeloma
This Phase 2 trial tests whether adding isatuximab and lenalidomide as long-term treatment after stem cell transplant can help keep high-risk multiple myeloma under control. It may help some people reduce the chance of the disease coming back after transplant.
Houston, TexasAges 18–72 - NCT05773001RecruitingPhase 1
Study of an immune treatment for ozone-related lung inflammation
This early-phase study tests how an immune-targeting treatment affects inflammation in the lungs after ozone exposure. It may help researchers understand—and eventually reduce—lung inflammation triggered by air pollution.
Durham, North CarolinaAges 18–55 - NCT05746039RecruitingPhase 1/Phase 2
Testing semaglutide for advanced lung disease
This study checks whether semaglutide is safe and feasible for people with advanced lung diseases and higher body weight. It may help by testing a structured treatment approach, but it includes several health and safety limits.
Philadelphia, PennsylvaniaAges 18–80 - NCT05758831RecruitingPhase 3
Rituximab vs ocrelizumab for relapsing multiple sclerosis
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
Lyon, BronAges 18–55 - NCT05774548Recruiting
Study of PrEP use and its cost in HIV prevention
This study looks at how taking PrEP (medicine to prevent HIV) affects HIV prevention and how much it costs in real life. You may be able to join if you are HIV-negative and are interested in starting, currently using, or have used PrEP before.
Bangkok, BangkapiAges 18 years+ - NCT05775224Enrolling by invitation
Join a research data hub for sickle cell or multiple myeloma
This study builds a database of people with sickle cell disease and/or active multiple myeloma (diagnosed or treated in recent years). It may help researchers learn how these illnesses behave and support better future studies or treatments.
Washington D.C., District of ColumbiaAges Any age - NCT05748015Recruiting
Checking how the nervous system is affected in multiple sclerosis
This study looks at signs of how your automatic “control” nerves (the autonomic nervous system) may be affected in people with multiple sclerosis. It may help researchers better understand different types of MS and how to recognize nervous-system involvement.
Telese Terme, BeneventoAges 18 years+ - NCT05752500Recruiting
Behavior coaching to help older adults with HIV move more
This study tests a tailored behavioral coaching program to increase physical activity in adults age 50+ who have HIV and are currently not very active. It may help you build safer, more routine movement using a Fitbit for tracking.
Minneapolis, MinnesotaAges 50 years+ - NCT05750498Recruiting
Study to improve outcomes in autoimmune liver disease
This trial tests approaches to improve health outcomes for people with autoimmune liver diseases. It includes specific autoimmune conditions affecting the liver and bile ducts, and it may help your care team learn what works best for these illnesses.
Palo Alto, CaliforniaAges Any age - NCT05760898Recruiting
Helping control blood pressure in people with rheumatoid arthritis
This study aims to improve blood pressure control in adults who have both uncontrolled high blood pressure and rheumatoid arthritis. It may help by testing ways to better coordinate care between primary care and rheumatology.
Durham, North CarolinaAges 18 years+ - NCT05772637Recruiting
Testing bladder feeling in people with multiple sclerosis
This study checks how your bladder “sensation” works using bladder testing (including urodynamic testing) to better understand MS-related bladder problems. It may help researchers match bladder symptoms to what’s happening inside the bladder.
Paris, Choisir Une RégionAges 18–99 - NCT04844528RecruitingPhase 2
Nicotinamide for CLL patients with recent skin cancer history
This Phase 2 trial tests whether nicotinamide (a form of vitamin B3) can help people with chronic lymphocytic leukemia (CLL) who have had non-melanoma skin cancers in the past 5 years. The study looks at how well new skin cancers can be prevented or reduced.
Salt Lake City, UtahAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,067 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,241 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.